Key Takeaways
- Eli Lilly's (LLY) experimental obesity drug, Retatrutide, demonstrated significant weight loss, with participants losing an average of 28.7% of their body weight (up to 71.2 lbs) in a Phase 3 trial, potentially surpassing existing treatments like Zepbound.
- The positive trial results for Retatrutide led to a 2.1% premarket surge in Eli Lilly shares and caused shares of competitor Novo Nordisk (NVO) to briefly turn negative, highlighting intense competition in the weight-loss drug market.
- Altria Group (MO) announced the retirement of CEO Billy Gifford, with Sal Mancuso named as his successor, signaling a leadership transition for the tobacco giant.
- China is leading objections to a potential reprieve by former President Trump on the global minimum tax, indicating ongoing international financial policy disputes.
Eli Lilly's Retatrutide Delivers Impressive Weight Loss Results
Eli Lilly and Company (LLY) has reported overwhelmingly positive topline data from its Phase 3 TRIUMPH-4 trial for Retatrutide, an investigational once-weekly treatment for obesity. The experimental triple agonist shot helped participants with obesity and knee osteoarthritis achieve an average body weight reduction of 28.7% over 68 weeks, with some losing up to 71.2 lbs. This performance reportedly tops that of Lilly's own Zepbound, an existing weight-loss drug, and has met all primary and key secondary endpoints in the trial.
The news sent Eli Lilly shares up 2.1% in premarket trading. The success of Retatrutide also had an immediate impact on competitors, with Novo Nordisk (NVO) shares briefly turning negative before recovering to trade up 1.8%. Eli Lilly expects to complete seven additional Phase 3 trials for Retatrutide in obesity and type 2 diabetes in 2026. Beyond weight loss, the trial also indicated that Retatrutide provides substantial pain relief for knee osteoarthritis, adding another potential benefit to the drug's profile.
Altria Announces CEO Transition
Altria Group (MO) is undergoing a leadership change as CEO Billy Gifford prepares to retire. Sal Mancuso has been named as his successor. This transition marks a significant development for the tobacco industry giant.
Global Minimum Tax Faces Chinese Opposition
Internationally, China is leading objections to a potential move by former President Trump to reprieve the global minimum tax. This stance highlights ongoing geopolitical tensions surrounding international corporate taxation policies.
Citigroup Upgrades Thermo Fisher Scientific
In analyst news, Citigroup has upgraded Thermo Fisher Scientific (TMO) to a 'Buy' rating from 'Neutral'. The firm also raised its price target for the scientific instrument maker to $660 from $580.
Market Overview
European bourses opened lower but later showed marginal firmness, while US equity futures were in the red, with underperformance noted in the Nasdaq following Oracle's (-11%) earnings report. The DXY initially attempted to pare post-FOMC pressure but is now flat, with the Swiss Franc showing little movement.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.